Total Payments
$244,667
2024 Payments
$29,255
Companies
3
Transactions
78
Medicare Patients
4,885
Medicare Billing
$166,121
Payment Breakdown by Category
Research$244,667 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $244,667 | 78 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $156,042 | 66 | $0 (2024) |
| Roche Products Limited | $82,205 | 10 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $6,420 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,255 | 13 | Regeneron Pharmaceuticals, Inc. ($29,255) |
| 2023 | $45,705 | 24 | Regeneron Pharmaceuticals, Inc. ($45,705) |
| 2022 | $87,237 | 26 | Regeneron Pharmaceuticals, Inc. ($57,342) |
| 2021 | $81,860 | 14 | Roche Products Limited ($52,310) |
| 2020 | $610.00 | 1 | E.R. Squibb & Sons, L.L.C. ($610.00) |
All Payment Transactions
78 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/05/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $1,575.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 08/07/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $1,575.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 08/07/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $840.00 | Research |
| Study: A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
| 06/18/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $1,800.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 06/18/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $1,575.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 06/07/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER | ||||||
| 06/07/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $170.00 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER | ||||||
| 06/07/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $60.00 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER | ||||||
| 04/04/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $4,050.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 04/04/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $3,600.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 04/04/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $360.00 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER | ||||||
| 01/05/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $8,775.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 01/05/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $4,275.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 12/14/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $3,120.00 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER | ||||||
| 12/14/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $480.00 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER | ||||||
| 12/12/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $4,050.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 12/12/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $3,600.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 12/12/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $360.00 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER | ||||||
| 12/12/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $360.00 | Research |
| Study: A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
| 10/17/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $1,925.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 10/17/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $120.00 | Research |
| Study: A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
| 10/06/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $700.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 10/06/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $480.00 | Research |
| Study: A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
| 09/21/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $1,400.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 09/21/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $1,200.00 | Research |
| Study: A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | Regeneron Pharmaceuticals, Inc. | $108,783 | 29 |
| PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | Roche Products Limited | $82,205 | 10 |
| A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | Regeneron Pharmaceuticals, Inc. | $34,460 | 28 |
| A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER | Regeneron Pharmaceuticals, Inc. | $12,798 | 9 |
| A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma | E.R. Squibb & Sons, L.L.C. | $6,420 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 887 | 1,085 | $118,835 | $25,179 |
| 2022 | 21 | 1,332 | 1,523 | $347,420 | $45,100 |
| 2021 | 20 | 1,426 | 1,665 | $217,451 | $50,836 |
| 2020 | 17 | 1,240 | 1,469 | $186,941 | $45,005 |
Total Patients
4,885
Total Services
5,742
Medicare Billing
$166,121
Procedure Codes
76
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2023 | 151 | 159 | $58,140 | $10,617 | 18.3% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2023 | 58 | 60 | $17,585 | $3,870 | 22.0% |
| 71045 | X-ray of chest, 1 view | Facility | 2023 | 261 | 437 | $14,283 | $3,242 | 22.7% |
| 74183 | Mri scan of abdomen before and after contrast | Office | 2023 | 20 | 20 | $5,520 | $1,688 | 30.6% |
| 71046 | X-ray of chest, 2 views | Facility | 2023 | 193 | 196 | $7,778 | $1,581 | 20.3% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 22 | 22 | $5,038 | $1,544 | 30.7% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 18 | 18 | $1,674 | $506.40 | 30.3% |
| 71250 | Ct scan of chest without contrast | Facility | 2023 | 11 | 11 | $1,818 | $477.51 | 26.3% |
| 71260 | Ct scan of chest with contrast | Facility | 2023 | 14 | 14 | $3,040 | $458.80 | 15.1% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 42 | 42 | $1,176 | $346.45 | 29.5% |
| 73562 | X-ray of knee, 3 views | Office | 2023 | 23 | 24 | $624.00 | $191.36 | 30.7% |
| 73564 | X-ray of knee, 4 or more views | Office | 2023 | 11 | 11 | $522.00 | $162.11 | 31.1% |
| 73630 | X-ray of foot, minimum of 3 views | Office | 2023 | 21 | 24 | $528.00 | $156.72 | 29.7% |
| 73130 | X-ray of hand, minimum of 3 views | Office | 2023 | 14 | 18 | $414.00 | $129.21 | 31.2% |
| 73030 | X-ray of shoulder, minimum of 2 views | Office | 2023 | 15 | 16 | $384.00 | $117.76 | 30.7% |
| 74018 | X-ray of abdomen, 1 view | Office | 2023 | 13 | 13 | $312.00 | $92.04 | 29.5% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2022 | 222 | 235 | $147,532 | $16,556 | 11.2% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2022 | 129 | 134 | $44,814 | $9,466 | 21.1% |
| 71045 | X-ray of chest, 1 view | Facility | 2022 | 313 | 442 | $29,198 | $3,295 | 11.3% |
| 74183 | Mri scan of abdomen before and after contrast | Facility | 2022 | 31 | 31 | $21,859 | $2,623 | 12.0% |
| 71250 | Ct scan of chest without contrast | Facility | 2022 | 60 | 61 | $17,826 | $2,594 | 14.6% |
| 71260 | Ct scan of chest with contrast | Facility | 2022 | 54 | 54 | $14,769 | $2,367 | 16.0% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Facility | 2022 | 24 | 24 | $19,450 | $1,915 | 9.8% |
| 71046 | X-ray of chest, 2 views | Facility | 2022 | 205 | 208 | $18,300 | $1,815 | 9.9% |
| 71275 | Ct scan of blood vessels of chest with contrast | Facility | 2022 | 16 | 16 | $4,802 | $1,125 | 23.4% |
About Dr. Nagaraj-Setty Holalkere, MD
Dr. Nagaraj-Setty Holalkere, MD is a Diagnostic Radiology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1497881106.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nagaraj-Setty Holalkere, MD has received a total of $244,667 in payments from pharmaceutical and medical device companies, with $29,255 received in 2024. These payments were reported across 78 transactions from 3 companies. The most common payment nature is "" ($244,667).
As a Medicare-enrolled provider, Holalkere has provided services to 4,885 Medicare beneficiaries, totaling 5,742 services with total Medicare billing of $166,121. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Other Specialties Diagnostic Radiology, Diagnostic Radiology
- Location Boston, MA
- Active Since 02/26/2007
- Last Updated 11/12/2025
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1497881106
Products in Payments
- TECENTRIQ (Biological) $82,205
- LIBTAYO (Biological) $34,460
- OPDIVO (Biological) $6,420
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Boston
Andrew Kompel, M.d, M.D
Diagnostic Radiology — Payments: $3.4M
Diagnostic Radiology $3.4M
Gregg Miller, M.d, M.D
Diagnostic Radiology — Payments: $3.0M
Diagnostic Radiology $3.0M
Stephan Anderson, M.d, M.D
Diagnostic Radiology — Payments: $2.4M
Diagnostic Radiology $2.4M
Ashraf Thabet, M.d, M.D
Diagnostic Radiology — Payments: $1.7M
Diagnostic Radiology $1.7M
Dr. Mukesh Harisinghani, Md, MD
Diagnostic Radiology — Payments: $1.4M
Diagnostic Radiology $1.4M
Subba Digumarthy, Md, MD
Diagnostic Radiology — Payments: $1.1M
Diagnostic Radiology $1.1M